NCT03706365Active, not recruitingPhase 2/3
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
Source: ClinicalTrials.gov · Last updated 7 Aug 2026
Brief summary (registry, in English)
This study is being done to see how safe and effective abemaciclib is when given together with abiraterone acetate plus prednisone in participants with metastatic castration resistant prostate cancer. Prednisolone may be used instead of prednisone per local regulation.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2/3
- Study type
- Interventional
- Enrollment
- 393 (actual)
- First submitted
- 18 Sept 2018
- Start date
- 26 Nov 2018
- Primary completion date
- 2 Jan 2024
- Lead sponsor
- Eli Lilly and Company
- Diseases
- Prostate cancer
- NCT number
- NCT03706365
- EU CT number
- 2023-506777-36-00
- EudraCT number
- 2016-004276-21
What you commit to
- Study type: Interventional · Phase 2/3
- Participants enrolled: 393
- From 26 Nov 2018 to the primary completion date, 2 Jan 2024
- 112 sites in 11 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
This page is information, not medical advice. Discuss any trial with your doctor.